西点药业 reported revenue of ¥0.10B for the period ended 2026-06-30, -21.0% year on year. Net income was ¥0.01B, a 7.7% net margin on a 74.1% gross margin. The largest revenue line is 其他主营业务 at 100% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.10B | -21.0% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | -66.7% |
| Gross margin | 74.1% | Net margin 7.7% |
| Revenue Q/Q | -18.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 其他主营业务 | ¥0.10B | 99.8% |
| 其他(补充) | ¥0.00B | 0.1% |
| 其他业务 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.03B | 25.9% |
| R&D | ¥0.00B | 4.9% |
| SG&A | ¥0.06B | 61.4% |
| Tax & other | ¥0.00B | 0.3% |
| Item | Amount |
|---|---|
| Total assets | ¥1.07B |
| Total liabilities | ¥0.16B |
| Shareholders' equity | ¥0.90B |
| Equity / assets | 84.6% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 354% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
聚赛龙 ・ 满坤科技 ・ 金钟股份 ・ 瑞德智能 ・ 招标股份 ・ 哈焊华通 ・ 华研精机 ・ *ST元道 ・ 中科磁业 ・ 嘉戎技术 ・ 隆华新材 ・ 中一科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies